Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Clinton, South Carolina 29325


Purpose:

The purpose of this study is to examine the healthcare costs among patients with CML receiving dasatinib or nilotinib as first line therapy in a commercially or Medicare insured population.


Criteria:

For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Age >18 years - International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9 CM) code for CML (205.1x) - At least 2 prescriptions for dasatinib or nilotinib from July 1, 2008 to June 31, 2013 - Continuous eligibility for the 6 months pre- and post-index date (defined as the date of first fill for dasatinib or nilotinib) Exclusion Criteria: - History of bone marrow or stem cell transplant as identified in the 6 month pre-period


NCT ID:

NCT02363868


Primary Contact:

Study Director
Bristol-Myers Squibb
Bristol-Myers Squibb


Backup Contact:

N/A


Location Contact:

Clinton, South Carolina 29325
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: November 20, 2017

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.